Cas9 Stable Cell Line - HuH-7

Established in 1982, the HuH-7 cell line, derived from a differentiated hepatocellular carcinoma in a 57-year-old Japanese man, is a widely used human liver cancer model. This epithelial-like adherent cell line exhibits strong proliferative capacity in vitro and retains key hepatocyte functions, including albumin secretion and drug-metabolizing enzymes. The Cas9 Stable Cell Line - HuH-7 is a genetically engineered derivative in which CRISPR-associated protein 9 (Cas9) is stably integrated into the HuH-7 genome. This cell line maintains stable Cas9 expression during passage without repeated transfection. Parental HuH-7 cells possess diploid chromosomes and support hepatitis C virus (HCV) replication, while Cas9-expressing variants, when used in conjunction with guide RNA (sgRNA), enable precise genome editing with an efficiency exceeding 90%.

The Cas9 Stable Cell Line - HuH-7 holds broad application prospects in biomedical research. In functional genomics, it can perform high-throughput CRISPR screening to identify key genes involved in hepatocellular carcinoma (HCC) proliferation, viral infection (HCV/HBV), or drug resistance mechanisms. Researchers utilize its stable Cas9 expression to rapidly construct gene knockout/knock-in models (e.g., TP53 or β-catenin mutants) to study the pathogenesis of HCC. Virologists use this cell line to elucidate host-virus interactions by targeting factors crucial to the HCV lifecycle, such as miR-122 or ApoE. Furthermore, this cell line can facilitate drug discovery by combining CRISPR screening libraries to identify synthetic lethal interactions for targeted therapy. Applications of this cell line also include metabolic research; for example, by modifying genes regulating lipid metabolism (such as SREBP) or glucose homeostasis, NAFLD/NASH models can be constructed.